• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Royalty Pharma Plc Cl A (NQ: RPRX )

    25.95 -0.05 (-0.21%)
    Streaming Delayed Price Updated: 12:16 PM EST, Nov 13, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Royalty Pharma Plc Cl A

    < Previous 1 2 3 4 5 6 7 Next >
    Earnings Scheduled For August 11, 2021
    Companies Reporting Before The Bell • Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second quarter. • Gamida Cell (NASDAQ:GMDA) is... 
    Via Benzinga
    The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
    Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
    Via Benzinga
    Exposures Product Safety
    Why MorphoSys Stock Sank This Week
    Investors weren't happy about the drugmaker's wheeling and dealing. 
    Via The Motley Fool
    Earnings Scheduled For May 11, 2021
    Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter. • ReWalk Robotics (NASDAQ:RWLK) is... 
    Via Benzinga
    Constellation Pharma Rockets On Word Of $1.7 Billion MorphoSys Takeover
    MorphoSys announced its $1.7 billion plan to acquire cancer treatment biotech Constellation on Wednesday and CNST stock rocketed to a four-month high. 
    Via Investor's Business Daily
    Royalty Pharma Insights: Return On Capital Employed
    Royalty Pharma (NASDAQ:RPRX) posted a 26.99% decrease in earnings from Q4. Sales, however, increased by 0.18% over the previous quarter to $573.03 million. Despite the increase in... 
    Via Benzinga
    MorphoSys to Acquire Constellation Pharma at $34/Share; Enters $2B Strategic Funding with Royalty Pharma
    MorphoSys AG (NASDAQ: MOR) has agreed to acquire Constellation Pharmaceuticals Inc (NASDAQ: CNST) for $34/share in cash, representing a total equity value of... 
    Via Benzinga
    Repros Therapeutics (RPRX) Q1 2021 Earnings Call Transcript
    RPRX earnings call for the period ending March 31, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Why Is GlaxoSmithKline Selling Its Income Stream to Royalty Pharma?
    Apparently, up-front capital is better than royalties on drugs the pharma doesn't have control over. 
    Via The Motley Fool
    The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -... 
    Via Benzinga
    Exposures COVID-19 Product Safety
    The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
    Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
    Via Benzinga
    Exposures COVID-19 Product Safety
    Insider Sells Royalty Pharma's Shares
    A Form 4 filing filed with the SEC on Wednesday, April 14 showed that EVP Reddoch James F. sold 359 shares of Royalty Pharma Inc (NASDAQ:RPRX) at an average price of $42.32... 
    Via Benzinga
    Topics Regulatory Compliance
    Exposures Legal Regulatory
    Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront
    Royalty Pharma plc (NASDAQ: RPRX) has acquired Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) royalty interest in Oxlumo (lumasiran) for an... 
    Via Benzinga
    Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million
    From Dicerna Pharmaceuticals, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.